Skip to main content

News Release

 
Printer Friendly Version View printer-friendly version
<< Back
HeartWare to Report 2009 Fourth Quarter and Year-End Financial Results
FRAMINGHAM, Mass. and SYDNEY, Feb 08, 2010 /PRNewswire via COMTEX/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX:HIN) will release financial results for the fourth quarter and year ended December 31, 2009, after the close of the U.S. markets on Monday, February 22, 2010.

A conference call with management is scheduled for 8:00 am U.S. Eastern Standard Time on Tuesday, February 23, 2010 (being midnight Australian Eastern Daylight Time, between February 23 and February 24, 2010) to discuss the Company's financial results and to provide a corporate update. The call may be accessed by dialing 1-877-407-9039 five minutes prior to the scheduled start time and referencing "HeartWare." For callers outside the United States, dial +1-201-689-8470.

A live web cast of the call will also be available at the Company's website (www.heartware.com) by selecting "HeartWare Fourth Quarter and Year-End Conference Call" under the section titled "Corporate Presentations" on the HOME page. A replay of the conference call will be available through the above weblink immediately following completion of the call.

The Company also expects to file its 10-K for the year December 31, 2009 on or about the date of the conference call.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIb and Class IV patients suffering from advanced heart failure. The HeartWare(R) Ventricular Assist System features the HVAD(TM) pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. HeartWare has received CE Marking for the HeartWare(R) Ventricular Assist System in the European Union. The device is currently the subject of a 150-patient clinical trial in the United States for a Bridge-to-Transplant indication.

HeartWare International, Inc. is a member of the Russell 2000(R) and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.



    For further information:
    ------------------------
    Christopher Taylor
    HeartWare International, Inc.
    Email: ctaylor@heartwareinc.com
    Phone: +1 508 739 0864



SOURCE HeartWare International, Inc.